annual

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism…

4 weeks ago

Deltek Celebrates the 18th Annual Most Valuable Project Award Winners at Deltek ProjectCon 2025

Global leaders across architecture, engineering, construction, consulting, and government contracting recognized for innovation using Deltek solutions HERNDON, Va., Nov. 11,…

4 weeks ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical…

4 weeks ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

November 03, 2025 16:45 ET  | Source: Fulcrum Therapeutics, Inc. ― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell…

1 month ago

Xinhua Silk Road: Annual Conference of Financial Street Forum 2025 concludes with fruitful results

BEIJING, Nov. 3, 2025 /PRNewswire/ -- The Annual Conference of Financial Street Forum 2025 concluded on Thursday with a theme…

1 month ago

Xinhua Silk Road: Annual Conference of Financial Street Forum 2025 kicks off Monday, highlighting high-quality global financial development

BEIJING, Oct. 30, 2025 /PRNewswire/ -- The Annual Conference of Financial Street Forum 2025 kicked off here on Monday, bringing…

1 month ago

PARTNERSHIP ANNUAL DINNER TO BRING THE ENERGY WITH BESTSELLING AUTHOR

GREATER DES MOINES, Iowa, Oct. 27, 2025 /PRNewswire/ -- The Greater Des Moines Partnership has announced that bestselling author and…

1 month ago

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…

1 month ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12…

2 months ago

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025 10:00 ET  | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…

2 months ago